The selling pressure regarding Renault shares could subside shortly. In fact, the support area that is currently being tested around 83 EUR has come into play and could, at least in the short term, keep the downside pressure at bay. Investors have an opportunity to buy the stock and target the € 88.5.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
Renault accounts for 4.34 % of our European Portfolio. A trade is currently open since 04/09/2015 with a purchase price of € 87.13. Discover the other 19 stocks of the European portfolio managed by the 4-traders portfolio management team.
The close medium term support offers good timing for purchasing the stock.
The group usually releases upbeat results with huge surprise rates.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.36 for the 2017 fiscal year.
Its low valuation, with P/E ratio at 5.43 and 5.39 for the ongoing fiscal year and 2018 respectively, makes the stock pretty attractive with regard to earnings multiples.
This company will be of major interest to investors in search of a high dividend stock.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.